The WACC of Innovaderma PLC (IDP.L) is 5.5%.
Range | Selected | |
Cost of equity | 6.3% - 8.5% | 7.4% |
Tax rate | 24.9% - 30.3% | 27.6% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 5.0% - 6.0% | 5.5% |
Category | Low | High |
Long-term bond rate | 2.9% | 3.4% |
Equity market risk premium | 5.3% | 6.3% |
Adjusted beta | 0.62 | 0.72 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.3% | 8.5% |
Tax rate | 24.9% | 30.3% |
Debt/Equity ratio | 1 | 1 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 5.0% | 6.0% |
Selected WACC | 5.5% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
IDP.L | Innovaderma PLC | 0.15 | 1.92 | 1.74 |
BIE.MI | Bioera SpA | 12.98 | -0.02 | 0 |
ENV.MI | Enervit SpA | 0.15 | 0.11 | 0.1 |
HRP.WA | Harper Hygienics SA | 3.66 | 0.3 | 0.08 |
MIR.WA | Miraculum SA | 0.55 | 0.39 | 0.28 |
MPH.WA | Master Pharm SA | 0.05 | 0.35 | 0.34 |
NATTO.OL | Nattopharma ASA | 0.02 | 1.22 | 1.2 |
NICO.ST | Nicoccino Holding AB (publ) | 0.03 | -1.29 | -1.26 |
ONTEX.BR | Ontex Group NV | 1.33 | 0.73 | 0.37 |
PHR.WA | Pharmena SA | 0.19 | 0.38 | 0.33 |
VLG.L | Venture Life Group PLC | 0.42 | 0.21 | 0.16 |
Low | High | |
Unlevered beta | 0.16 | 0.33 |
Relevered beta | 0.43 | 0.58 |
Adjusted relevered beta | 0.62 | 0.72 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for IDP.L:
cost_of_equity (7.40%) = risk_free_rate (3.15%) + equity_risk_premium (5.80%) * adjusted_beta (0.62) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.